Innodem Neurosciences, a leading digital health and AI company, announced today that its ETNA™-MS has been cleared for commercial use by Health Canada. The Eye Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) is a software as a medical device (SaMD, Class II) intended to administer a non-invasive test and provide an Expanded Disability Status Scale (EDSS) score in the range between 1.0 and 4.5 for use in tracking disease progression in MS patients.